Swiss Life Sciences Stock News

Idorsia (SWX:IDIA) is back in focus after announcing that CEO Dr. Srishti Gupta will step down and also leave the Board of Directors. Chairman Jean Paul Clozel will take over as interim CEO. See our latest analysis for Idorsia. The leadership change comes after a mixed period for investors, with the latest CHF3.15 share price sitting against a 1 day share price return of 2.27%, a 30 day share price return of a 14.75% decline, and a very large 1 year total shareholder return of about 3x...

Compagnie Financière Tradition (SWX:CFT) has reported FY 2025 results with first half revenue of CHF 575.4 million and basic EPS of CHF 9.14, while trailing twelve month revenue came in at about CHF 1.1 billion with EPS of CHF 16.25 and earnings growth of 21.7% over the past year. Over recent periods the company has seen revenue move from CHF 533.4 million and EPS of CHF 7.98 in 1H 2024 to CHF 510.5 million and EPS of CHF 7.13 in 2H 2024, before reaching the latest 1H 2025 levels. This sets...

Liechtensteinische Landesbank (SWX:LLBN) has drawn investor attention after issuing a CHF 200 million senior preferred bond, a ten year fixed rate instrument that met strong demand and references the bank’s solid capital position. See our latest analysis for Liechtensteinische Landesbank. The bond issue comes as the share price trades at CHF98.8, with a 1-day share price return of 1.96% and a 90-day share price return of 18.61%. The 1-year total shareholder return of 28.92% and 5-year total...

Novartis (SWX:NOVN) agreed to acquire a selective breast cancer therapy targeting PI3Kα mutations from Synnovation Therapeutics for up to US$3b. The oral therapy is aimed at HR+/HER2- breast cancer with PI3Kα mutations, addressing a major unmet treatment need. The deal is intended to strengthen Novartis's targeted oncology portfolio in a competitive cancer drug market. For investors watching big pharma, this move puts a fresh spotlight on Novartis's focus on targeted cancer medicines...

Assessing Alcon after recent share price pressure Alcon (SWX:ALC) has come under pressure recently, with the share price showing negative returns over the past month and past 3 months. This puts the focus on what current fundamentals might imply for investors. See our latest analysis for Alcon. Beyond the recent pullback, Alcon’s share price return has been weak over the year, and the 1 year total shareholder return of a 26.9% decline underlines that pressure has been sustained rather than a...

Galderma Group (SWX:GALD) has scheduled a virtual Annual General Meeting that will focus on corporate governance changes. The AGM agenda includes new board nominations linked to major shareholder L’Oréal and a proposed dividend. Management plans to discuss L’Oréal’s influence as an investor following a period of record company performance. Galderma Group operates in the dermatology and skincare segment, an area that continues to attract consumer interest as spending on skin health and...

Roche Holding (SWX:ROG) has drawn investor attention after recent price moves, with the share price around CHF 322.30 and mixed short term returns contrasting with stronger multi year total return figures. See our latest analysis for Roche Holding. Recent trading has been choppy, with a 1 month share price return showing a decline of 10.47% and a year to date share price return showing a decline of 0.98%, contrasting with a 1 year total shareholder return of 10.30%. This suggests that recent...

If you are wondering whether UBS Group's current share price offers value or just noise, the recent performance gives you plenty to think about. The stock trades at CHF 29.08, with a 0.7% decline over the last week, a 12.9% decline over the last month, a 23.8% decline year to date, a 4.2% gain over 1 year, 83.3% over 3 years and 120.0% over 5 years. These moves sit against a backdrop of ongoing integration work following the Credit Suisse acquisition and continuing market attention on UBS...

Swiss Re (SWX:SREN) has attracted fresh attention after striking a US$2b longevity reinsurance deal with Athene, its first covering US retirees and a step that broadens its role in global pension risk transfer. See our latest analysis for Swiss Re. The longevity deal and recent leadership change in the Asia Pacific life and health unit come as Swiss Re’s share price sits at CHF128.0, with a small year to date share price decline and a much stronger multi year total shareholder return profile...

Recent share performance and business overview SMG Swiss Marketplace Group Holding (SWX:SMG) has drawn interest after a period of weaker share performance, with the stock closing at CHF 26.35 and showing negative returns over the past week, month and past 3 months. The company runs online marketplaces across real estate, automotive and general classifieds in Switzerland. It earned CHF 358.843m in revenue and CHF 67.694m in net income, supported by reported annual revenue and net income growth...

Nestlé Holdings has completed a major cash tender offer for its outstanding notes, purchasing all securities that were validly tendered. The transaction used available liquidity and may have involved intra group distributions from Nestlé, affecting how debt is positioned within the group. This liability management move changes the mix of outstanding debt and could affect interest costs and balance sheet flexibility over time. For readers tracking SWX:NESN, this development comes with the...

Partners Group Holding (SWX:PGHN) is back in the spotlight after a Bank of America note highlighted its exposure to potential private credit shocks, just as the chair mentioned a possible doubling of default rates. See our latest analysis for Partners Group Holding. The recent Bank of America note appears to have reinforced concerns around private credit risk. This lines up with Partners Group Holding's 1 month share price return of 14.86% decline and year to date share price return of 22.02%...

Swiss Life Holding (SWX:SLHN) just combined its 2025 earnings release with an increased annual dividend of CHF 36.50 per share, a pairing that tends to draw income focused investors’ attention. See our latest analysis for Swiss Life Holding. The share price has softened recently, with a 1 month share price return of 3.15% and a 90 day share price return of 8.72%. However, the 1 year total shareholder return of 10.22% and 5 year total shareholder return of 127.70% point to stronger longer term...

Givaudan, ticker SWX:GIVN, is participating in the Future Food-Tech San Francisco event. The company is highlighting its front end innovation capabilities, with its Head of Front End Innovation presenting. The event participation puts a spotlight on Givaudan's role in emerging food technology trends and potential collaboration opportunities. Givaudan enters this conference with its share price at CHF2,701.0 and a value score of 4, reflecting how some investors may currently view the stock...

Dividend announcement and earnings call set the tone Stadler Rail (SWX:SRAIL) has attracted fresh attention after announcing an annual dividend of CHF 0.50 per share, alongside its 2025 earnings call held on 18 March 2026. The dividend is scheduled for payment on 11 May 2026, with the shares trading ex dividend on 7 May and a record date of 8 May. This provides investors with clear timelines around the cash distribution. See our latest analysis for Stadler Rail. Stadler Rail’s CHF 19.67 share...

Swissquote Group Holding (SWX:SQN) has put up a busy FY 2025 scorecard, with second half revenue of CHF 388.1 million and basic EPS of CHF 13.88 sitting alongside trailing twelve month revenue of CHF 760.8 million and EPS of CHF 24.49, underpinned by reported earnings growth of 24.6% over the last year. The company has seen revenue move from CHF 356.9 million in the second half of 2024 to CHF 372.7 million in the first half of 2025 and CHF 388.1 million in the second half of 2025, while net...

DocMorris (SWX:DOCM) has released fresh numbers for FY 2025, with first half revenue of CHF 541.5 million and a basic EPS loss of CHF 2.11 setting the tone, while over the trailing twelve months revenue reached CHF 1.1 billion against a basic EPS loss of CHF 3.47. Over recent periods, revenue has moved from CHF 496.3 million in H1 2024 to CHF 520.8 million in H2 2024 and CHF 541.5 million in H1 2025, as EPS has remained negative across all these halves. For investors, this mix of higher sales...

Swatch Group (SWX:UHR) has delivered a soft set of FY 2025 numbers, with second half revenue of CHF 3.2b and net income excluding extra items of essentially break even, alongside a current share price of CHF 164.45. The company has seen half year revenue move from CHF 3.3b in second half 2024 to CHF 3.1b in first half 2025 and CHF 3.2b in second half 2025. Net income excluding extra items shifted from CHF 57m to CHF 3m and then to zero over the same periods, setting up a story where wafer...

Logitech International (SWX:LOGN) has appointed Yalcin Yilmaz as its new Chief Commercial Officer, marking a key shift in its leadership team. The board has approved a new three year share buyback program, signaling a clear capital return plan for shareholders. The company has expanded its Racing Series Ecosystem with the launch of the RS H Shifter, adding a fresh product to its simulation portfolio. Logitech International, trading at CHF71.12, sits at an interesting point for investors...

Swisscom (SWX:SCMN) is in the spotlight after announcing a collaboration with Telecom Italia to develop up to 6,000 mobile tower sites across Italy, a move that extends its existing international infrastructure footprint. See our latest analysis for Swisscom. At a share price of CHF704.5, Swisscom has seen modest short term softness, with a 1 day share price return of a 1.1% decline and a 7 day share price return of a 0.8% decline. However, the 90 day share price return of 23.7% and 1 year...

Roche Holding's Ionify steroid assays for mass spectrometry have received U.S. FDA moderate complexity classification, widening access to advanced steroid hormone testing in clinical labs. Roche Pharma India has signed an MoU with NIPER Raebareli to collaborate on pharmaceutical education and research. These developments relate to both Roche's diagnostics portfolio and its global R&D footprint, including activity in India. Roche Holding (SWX:ROG) is drawing attention with regulatory...

UBS Group (SWX:UBSG) experienced a global technology outage that briefly halted parts of its trading operations. The disruption affected certain trading systems across regions before services were restored. The outage comes while UBS is integrating Credit Suisse's data and infrastructure following the recent acquisition. The incident adds to a series of similar technology disruptions reported at other large financial institutions. For you as an investor, this outage sits at the intersection...

EPIC Suisse (SWX:EPIC) issued 2026 guidance pointing to 2% to 3% net rental income growth, supported by completed developments PULSE and Campus Leman, and proposed lifting its dividend to CHF 3.20 per share. See our latest analysis for EPIC Suisse. The latest guidance and dividend proposal come after a period of steadier momentum, with a 90 day share price return of 8.39% and a 1 year total shareholder return of 20.90%, highlighting how sentiment has improved over a longer horizon. If this...

SMG Swiss Marketplace Group Holding (SWX:SMG) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 175.8 million and basic EPS of CHF 11.48, providing a clear reference point against last year’s CHF 152.2 million in revenue and CHF 8.99 EPS for the same period. The company has seen revenue move from CHF 152.2 million to CHF 175.8 million and EPS shift from CHF 8.99 to CHF 11.48 year on year for the first half. Trailing 12 month figures show EPS ranging between CHF...